Caxton Associates (New York)’s Medifast MED Stock Holding History

Caxton Associates (New York)’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,170	Closed	-$536K	–	591
2023 Q1	$536K	Buy	+5,170	New	+$573K	0.08%	246
2022 Q2	–	Sell	-1,396	Closed	-$238K	–	668
2022 Q1	$238K	Buy	1,396 +157	+13%	+$29.6K	0.02%	407
2021 Q4	$259K	Buy	1,239 +78	+7%	+$16.1K	0.03%	451
2021 Q3	$224K	Sell	1,161 -1,698	-59%	-$417K	0.02%	380
2021 Q2	$809K	Buy	2,859 +585	+26%	+$159K	0.09%	97
2021 Q1	$482K	Buy	+2,274	New	+$544K	0.04%	169
2020 Q4	–	Sell	-2,388	Closed	-$393K	–	250
2020 Q3	$393K	Buy	+2,388	New	+$393K	0.04%	144
2018 Q3	–	Sell	-2,104	Closed	-$337K	–	492
2018 Q2	$337K	Buy	+2,104	New	+$269K	0.02%	301
2017 Q2	–	Sell	-10,637	Closed	-$472K	–	528
2017 Q1	$472K	Buy	+10,637	New	+$458K	﹤0.01%	263

Other funds holding MED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Caxton Associates (New York)'s MED Position: Q2 2023 in Review

Caxton Associates (New York) sold out of Medifast (MED) in Q2 2023, closing a stake of 5,170 shares — an estimated $536K sold.

Caxton Associates (New York) first reported a position in MED in Q1 2017 and held it in 9 quarters. The position peaked at $809K in Q2 2021. 236 funds tracked by Wall St. Rank hold MED as of Q2 2023.

Caxton Associates (New York) reported no remaining Medifast position as of Q2 2023 after selling out during the quarter.
Caxton Associates (New York) sold 5,170 Medifast shares in Q2 2023, an estimated $536K.
Caxton Associates (New York) first reported a position in Medifast in Q1 2017 and held it in 9 quarters.
Caxton Associates (New York)'s Medifast position peaked at $809K in Q2 2021.
236 funds tracked by Wall St. Rank held Medifast as of Q2 2023.

Based on Caxton Associates (New York)'s 13F filing for Q2 2023, filed 15 Aug 2023.